Published in Hepatitis Weekly, April 27th, 2009
"In phase I clinical trials, monotherapy with boceprevir led to a distinct viral load reduction. In phase Ib combination trials of boceprevir with PEGylated IFN alpha 2b and ribavirin, the reduction in viral replication was further increased. Early data reported from phase II clinical trials have been promising, suggesting a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.